MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Price, Quote, News and Overview
NASDAQ:MRVI - Nasdaq - US56600D1072 - Common Stock - Currency: USD
MRVI Quote, Performance and Key Statistics
2.25
-0.15 (-6.25%)
The current stock price of MRVI is 2.25 USD. In the past month the price increased by 7.14%. In the past year, price decreased by -79.26%.
MRVI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 18.19 | 150.35B | ||
| DHR | DANAHER CORP | 25.08 | 133.69B | ||
| A | AGILENT TECHNOLOGIES INC | 20.51 | 31.05B | ||
| IQV | IQVIA HOLDINGS INC | 12.15 | 24.21B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 28.01 | 23.62B | ||
| WAT | WATERS CORP | 29.17 | 20.67B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.47 | 15.01B | ||
| ILMN | ILLUMINA INC | 23.83 | 12.56B | ||
| RVTY | REVVITY INC | 18.22 | 10.79B | ||
| ICLR | ICON PLC | 9.23 | 10.45B | ||
| TEM | TEMPUS AI INC | N/A | 10.06B | ||
| QGEN | QIAGEN N.V. | 18.4 | 9.15B |
Related stock screener links
About MRVI
Company Profile
Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 570 full-time employees. The company went IPO on 2020-11-20. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. The company serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Company Info
MARAVAI LIFESCIENCES HLDGS-A
10770 Wateridge Circle Suite 200, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Carl Hull
Employees: 580
Phone: 18585460004
MARAVAI LIFESCIENCES HLDGS-A / MRVI FAQ
What is the stock price of MARAVAI LIFESCIENCES HLDGS-A today?
The current stock price of MRVI is 2.25 USD. The price decreased by -6.25% in the last trading session.
What is the ticker symbol for MARAVAI LIFESCIENCES HLDGS-A stock?
The exchange symbol of MARAVAI LIFESCIENCES HLDGS-A is MRVI and it is listed on the Nasdaq exchange.
On which exchange is MRVI stock listed?
MRVI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MARAVAI LIFESCIENCES HLDGS-A stock?
20 analysts have analysed MRVI and the average price target is 5.95 USD. This implies a price increase of 164.58% is expected in the next year compared to the current price of 2.25. Check the MARAVAI LIFESCIENCES HLDGS-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MARAVAI LIFESCIENCES HLDGS-A worth?
MARAVAI LIFESCIENCES HLDGS-A (MRVI) has a market capitalization of 572.94M USD. This makes MRVI a Small Cap stock.
How many employees does MARAVAI LIFESCIENCES HLDGS-A have?
MARAVAI LIFESCIENCES HLDGS-A (MRVI) currently has 580 employees.
What are the support and resistance levels for MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?
MARAVAI LIFESCIENCES HLDGS-A (MRVI) has a support level at 2.12 and a resistance level at 2.41. Check the full technical report for a detailed analysis of MRVI support and resistance levels.
Is MARAVAI LIFESCIENCES HLDGS-A (MRVI) expected to grow?
The Revenue of MARAVAI LIFESCIENCES HLDGS-A (MRVI) is expected to decline by -25.42% in the next year. Check the estimates tab for more information on the MRVI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MRVI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MRVI, evaluating the profitability, health, valuation and growth aspects
- MARAVAI LIFESCIENCES HLDGS-A (MRVI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MARAVAI LIFESCIENCES HLDGS-A (MRVI) Sales and EPS estimates to see what analysts future expectations are.
- MARAVAI LIFESCIENCES HLDGS-A (MRVI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MARAVAI LIFESCIENCES HLDGS-A (MRVI) Insider and Institutional Ownership to learn about the owners and their transactions.
- MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Chart to make your own analysis
- MARAVAI LIFESCIENCES HLDGS-A (MRVI) Latest news and press-releases to stay up to date.
Does MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock pay dividends?
MRVI does not pay a dividend.
When does MARAVAI LIFESCIENCES HLDGS-A (MRVI) report earnings?
MARAVAI LIFESCIENCES HLDGS-A (MRVI) will report earnings on 2025-08-05, after the market close.
What is the Price/Earnings (PE) ratio of MARAVAI LIFESCIENCES HLDGS-A (MRVI)?
MARAVAI LIFESCIENCES HLDGS-A (MRVI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.16).
What is the Short Interest ratio of MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?
The outstanding short interest for MARAVAI LIFESCIENCES HLDGS-A (MRVI) is 11.93% of its float. Check the ownership tab for more information on the MRVI short interest.
MRVI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MRVI. When comparing the yearly performance of all stocks, MRVI is a bad performer in the overall market: 96.96% of all stocks are doing better.
MRVI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MRVI. While MRVI seems to be doing ok healthwise, there are quite some concerns on its profitability.
MRVI Financial Highlights
Over the last trailing twelve months MRVI reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS decreased by -700% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.95% | ||
| ROE | -54.13% | ||
| Debt/Equity | 1.07 |
MRVI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 74% to MRVI. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of -184.14% and a revenue growth -25.42% for MRVI